Cadrenal Therapeutics Reports Mixed Phase 2 Results for CAD-1005 in HIT; Advances to FDA End-of-Phase 2 Meeting
CVKD sits 41% above its 52-week low of $4.91.
Summary
Cadrenal Therapeutics announced Phase 2 trial results for CAD-1005 in heparin-induced thrombocytopenia (HIT), missing its primary endpoint but showing encouraging reductions in thrombotic events, leading to an upcoming FDA End-of-Phase 2 meeting.
Key Events · Product Development and Regulatory · CVKD
-
Phase 2 Trial Results Announced
The company reported results from its Phase 2 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT).
-
Primary Endpoint Missed
The trial did not meet its primary endpoint of platelet count recovery rate.
-
Encouraging Secondary Endpoint Data
CAD-1005 showed a greater than 25% absolute reduction in thrombotic events compared to placebo, though the study was not powered for statistical significance on this secondary endpoint.
-
FDA End-of-Phase 2 Meeting Scheduled
An End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) is scheduled for March 2026 to discuss a Phase 3 registration path for CAD-1005.
Analysis · CVKD · Life Sciences
Cadrenal Therapeutics' Phase 2 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT) presented mixed results. While the primary endpoint of platelet count recovery rate was not met, the drug demonstrated an encouraging reduction in thrombotic events in the secondary endpoint analysis. This suggests a potential clinical benefit despite the primary endpoint miss. The company's decision to proceed with an End-of-Phase 2 meeting with the FDA in March 2026 is a critical next step, indicating a potential path forward for Phase 3 development. Investors should monitor the outcome of this FDA meeting for clarity on the drug's regulatory future and the company's strategy for this first-in-class 12-LOX inhibitor.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVKD was trading at $6.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $4.91 to $22.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.